| abstract |
Disclosed is the use of a sphingosine-1-phosphate (S1P) receptor agonist compound of formula I wherein the substituents are as defined in the specification for the manufacture of a medicament for treating, alleviating or delaying the progression of optic neuritis. Also disclosed is the use of a the S1P agonist compound defined above with in combination with at least one co-agent shown to have clinical activity against a symptom of a de-myelinating disease for treating, alleviating of delaying progression of optic neuritis. |